ArticleJSES international2026
Is the St. Gallen Algorithm for proximal humerus fractures associated with improved outcomes?
Article in JSES international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proximal humerus fractures are the fourth most common type of fracture in elderly humans, seventh most common overall, and their incidence is rising. In 2019, the St. Gallen Algorithm (SGA) for treatment of proximal humerus fractures was proposed to improve treatment outcomes and reduce secondary surgeries. To date, no external validation of this algorithm has been reported. Methods: We performed a retrospective validation study with patients who sustained an isolated proximal humerus fracture between January 2010 and December 2020 at our institution. We calculated the prevalence of patients following the SGA and compared failure rates and Subjective Shoulder Value scores between those following the SGA and not. We also evaluated the entire cohort for predictors of treatment failure. Results: The prevalence of patients receiving treatment based on the SGA at our institution was 43% (n = 316). The overall failure rate was 13% (94/730 patients) at a mean follow-up of 22 months. The failure rate was 11% (36/316 patients) for the SGA group and 14% (58/414 patients) for the non-SGA group ( Conclusion: Following the SGA produced similar results to not following the SGA in terms of failure rate, survivorship, and clinical outcome scores. However, multivariate analysis identifies following the SGA as protective against failure. The findings of this study provide supportive but not definitive evidence for the clinical utility of the SGA as a decision-making aid in the treatment of proximal humerus fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.